Category: Sanofi-AventisSyndicate content

Diabetes: Medtronic and Sanofi ally on new drug-device combinations

June 16, 2014 by Arezu Sarvestani

Medtronic and Sanofi embark on a global alliance to combine human and financial resources in the interest of new products and services for patients with diabetes.

Diabetes: Medtronic and Sanofi ally for drug-device combinations

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Whistleblower lawsuit costs Genzyme $22M

January 3, 2014 by Arezu Sarvestani

Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product.

Whistleblower lawsuit costs Genzyme $22M

Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Brokers plead guilty to insider trading of Stryker stock

November 14, 2013 by Brad Perriello

A pair of brokers plead guilty to charges of insider trading in Stryker Corp. stock ahead of its 2011 acquisition of Orthovita.

Brokers plead guilty to insider trading of Stryker stock

A pair of brokers pleaded guilty to federal insider trading charges yesterday, admitting that they used tips from a former Stryker (NYSE:SYK) marketing executive to make illicit trades ahead of the medical device company's 2011 acquisition of Orthovita.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Unilife shares surge on MedImmune deal

November 13, 2013 by Chris Walker

Unilife shares are up more than 24% this week on news of a deal with MedImmune, the biologics arm of pharmaceuticals giant AstraZeneca.

Unilife shares surge on MedImmune Deal

Unilife (NSDQ:UNIS) shares are up more than 24% this week on a supply deal for its wearable injectors it inked with MedImmune, the biologics division of pharma giant AstraZeneca (NYSE:AZN).

Forbes articles were a 'vindictive attack on me personally,' says Unilife CEO

September 12, 2013 by Arezu Sarvestani

Unilife CEO Alan Shortall says a pair of Forbes articles were "vindictive," "malicious" and a "slap in the face" to analysts and portfolio managers who put their trust in the company.

Unilife takes issue with Forbes article on whistleblower lawsuit

Sanofi's last on the list to buy Bayer's glucose devices | MassDevice.com On Call

December 10, 2012 by MassDevice staff

French healthcare giant Sanofi is the last buyer still in the running to acquire German Bayer's blood glucose management devices, a deal that may be worth more than $1.5 billion, sources say.

MassDevice On Call

Is Johnson & Johnson eyeing Edwards, St. Jude? | MassDevice.com On Call

May 2, 2012 by MassDevice staff

Johnson & Johnson, already the world's largest health products maker, could have its eye on Edwards Lifesciences and St. Jude Medical as potential acquisitions, analysts say.

MassDevice On Call
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp